Explore Business Standard
Abbott Healthcare
Abbott, a global healthcare company, on Thursday announced the launch of a new and advanced formulation of 'Ensure Diabetes Care' in India. Building on over 30 years of pioneering scientific nutrition and supported by more than 60 clinical trials, the innovation empowers people with diabetes to live a better life, it said in a statement. The new design features a triple care system with vital nutrients, including four times higher myo-inositol compared to the previous formulation, a low glycaemic index carbohydrate blend, which is designed to help minimise blood sugar spikes. Combined with high protein and high fibre, the nutrients work together to support blood sugar control, help reduce cholesterol, and aid in weight management, the US-based healthcare company said. The formulation also helps preserve lean muscle during weight loss, while significantly reducing overall body fat, including visceral fat -- stored deep in the belly around organs like the liver and pancreas -- which is
Global healthcare company Abbott on Monday announced the launch of a dual-chamber leadless pacemaker system, which will help the heart beat properly without wires or surgical pockets used in traditional pacemakers. Pacemakers help keep the heart beating at a healthy pace, especially in the case of bradycardia, a condition where the heart beats too slowly. In a statement, Abbott said its implant-to-implant device technology enables wireless communication and synchronisation between two leadless pacemakers, which are smaller than an AAA battery. Until recently, leadless pacemakers could only support one chamber of the heart, because getting two separate devices to work together in sync was a major challenge. "As leadless pacing technology has evolved, we've built upon our AVEIR VR single-chamber platform to expand the benefits of leadless pacing to far more people and provide additional treatment options to patients," said Ajay Singh Chauhan, General Manager for Abbott's cardiac rhyt
Drug firm Abbott has launched a pacemaker in India for the treatment of patients with slow heart rhythms. Abbott has introduced AVEIR VR single-chamber ventricular leadless pacemaker which has been approved by the Central Drugs Standard Control Organisation, the company said in a statement on Friday. The product has also been approved by the US Food and Drug Administration (USFDA). "The AVEIR VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Ajay Singh Chauhan, General Manager for Abbott's Cardiac Rhythm Management business in India, Southeast Asia, HK, Taiwan & Korea. People who experience slower-than-normal heart rhythm may receive a pacemaker to deliver pulses of electricity to trigger the heart to beat properly. Balbir Singh, Chairman Cardiology, Max Superspeciality Hospital said, "Leadless pacemakers address known complications associated with ...
Drug firm Abbott India on Wednesday said its net profit increased by 13 per cent year on year to Rs 328 crore for the first quarter ended June 30, 2024. The company reported a net profit of Rs 290 crore in the April-June quarter of last fiscal. Total income rose to Rs 1,625 crore for the period under review as against Rs 1,535 crore in the June quarter of FY24, Abbott India said in a regulatory filing. Shares of the company on Wednesday ended 1.29 per cent up at Rs 28,159.95 apiece on the BSE.